These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
(State or other jurisdiction of incorporation or organization)
|
|
51-0263969
(I.R.S. Employer Identification No.)
|
|
|
|
6901 Professional Pkwy. East, Suite 200
Sarasota, Florida
(Address of principal executive offices)
|
|
34240
(Zip Code)
|
þ
Large accelerated filer
|
o
Accelerated filer
|
|
|
o
Non-accelerated filer (Do not check if a smaller reporting company)
|
o
Smaller reporting company
|
|
|
|
o
Emerging growth company
|
|
|
Page
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net revenues
|
$
|
1,159,912
|
|
|
$
|
945,144
|
|
|
$
|
3,380,888
|
|
|
$
|
2,779,125
|
|
Cost of sales
|
433,492
|
|
|
366,651
|
|
|
1,281,204
|
|
|
1,073,593
|
|
||||
Gross profit
|
726,420
|
|
|
578,493
|
|
|
2,099,684
|
|
|
1,705,532
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Selling, general and administrative expenses
|
415,673
|
|
|
311,103
|
|
|
1,236,423
|
|
|
940,073
|
|
||||
Income from operations
|
310,747
|
|
|
267,390
|
|
|
863,261
|
|
|
765,459
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Interest expense, net
|
45,523
|
|
|
26,800
|
|
|
137,201
|
|
|
81,076
|
|
||||
Other income/(expense), net
|
(659
|
)
|
|
(534
|
)
|
|
5,263
|
|
|
(1,997
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Earnings before income taxes
|
264,565
|
|
|
240,056
|
|
|
731,323
|
|
|
682,386
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Income taxes
|
74,292
|
|
|
72,977
|
|
|
203,423
|
|
|
205,822
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net earnings
|
$
|
190,273
|
|
|
$
|
167,079
|
|
|
$
|
527,900
|
|
|
$
|
476,564
|
|
|
|
|
|
|
|
|
|
||||||||
Net earnings per share:
|
|
|
|
|
|
|
|
||||||||
Basic
|
$
|
1.86
|
|
|
$
|
1.65
|
|
|
$
|
5.17
|
|
|
$
|
4.71
|
|
Diluted
|
$
|
1.84
|
|
|
$
|
1.63
|
|
|
$
|
5.11
|
|
|
$
|
4.65
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
||||||||
Basic
|
102,303
|
|
|
101,372
|
|
|
102,091
|
|
|
101,231
|
|
||||
Diluted
|
103,680
|
|
|
102,522
|
|
|
103,397
|
|
|
102,424
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Dividends declared per common share
|
$
|
0.35
|
|
|
$
|
0.30
|
|
|
$
|
1.05
|
|
|
$
|
0.90
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net earnings
|
$
|
190,273
|
|
|
$
|
167,079
|
|
|
$
|
527,900
|
|
|
$
|
476,564
|
|
|
|
|
|
|
|
|
|
||||||||
Other comprehensive income/(loss), net of tax:
|
|
|
|
|
|
|
|
||||||||
Foreign currency translation adjustments
|
67,535
|
|
|
9,054
|
|
|
147,462
|
|
|
(35,673
|
)
|
||||
Total other comprehensive income/(loss), net of tax
|
67,535
|
|
|
9,054
|
|
|
147,462
|
|
|
(35,673
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Comprehensive income
|
$
|
257,808
|
|
|
$
|
176,133
|
|
|
$
|
675,362
|
|
|
$
|
440,891
|
|
|
September 30,
2017 |
|
December 31,
2016 |
||||
ASSETS:
|
|
|
|
||||
|
|
|
|
||||
Cash and cash equivalents
|
$
|
605,616
|
|
|
$
|
757,200
|
|
Accounts receivable, net
|
603,874
|
|
|
619,854
|
|
||
Inventories, net
|
209,306
|
|
|
181,952
|
|
||
Unbilled receivables
|
157,852
|
|
|
129,965
|
|
||
Other current assets
|
115,408
|
|
|
87,530
|
|
||
Total current assets
|
1,692,056
|
|
|
1,776,501
|
|
||
|
|
|
|
||||
Property, plant and equipment, net
|
141,279
|
|
|
141,318
|
|
||
Goodwill
|
8,793,956
|
|
|
8,647,142
|
|
||
Other intangible assets, net
|
3,502,687
|
|
|
3,655,843
|
|
||
Deferred taxes
|
32,459
|
|
|
30,620
|
|
||
Other assets
|
84,236
|
|
|
73,503
|
|
||
|
|
|
|
||||
Total assets
|
$
|
14,246,673
|
|
|
$
|
14,324,927
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY:
|
|
|
|
||||
|
|
|
|
||||
Accounts payable
|
$
|
163,719
|
|
|
$
|
152,067
|
|
Accrued compensation
|
168,931
|
|
|
161,730
|
|
||
Deferred revenue
|
534,562
|
|
|
488,399
|
|
||
Other accrued liabilities
|
261,457
|
|
|
219,339
|
|
||
Income taxes payable
|
46,575
|
|
|
22,762
|
|
||
Current portion of long-term debt, net
|
401,534
|
|
|
400,975
|
|
||
Total current liabilities
|
1,576,778
|
|
|
1,445,272
|
|
||
|
|
|
|
||||
Long-term debt, net of current portion
|
4,932,721
|
|
|
5,808,561
|
|
||
Deferred taxes
|
1,163,371
|
|
|
1,178,205
|
|
||
Other liabilities
|
114,819
|
|
|
104,024
|
|
||
Total liabilities
|
7,787,689
|
|
|
8,536,062
|
|
||
|
|
|
|
||||
Commitments and contingencies (Note 9)
|
|
|
|
|
|
||
|
|
|
|
||||
Common stock
|
1,043
|
|
|
1,036
|
|
||
Additional paid-in capital
|
1,591,039
|
|
|
1,489,067
|
|
||
Retained earnings
|
5,062,926
|
|
|
4,642,402
|
|
||
Accumulated other comprehensive loss
|
(177,277
|
)
|
|
(324,739
|
)
|
||
Treasury stock
|
(18,747
|
)
|
|
(18,901
|
)
|
||
Total stockholders' equity
|
6,458,984
|
|
|
5,788,865
|
|
||
|
|
|
|
||||
Total liabilities and stockholders' equity
|
$
|
14,246,673
|
|
|
$
|
14,324,927
|
|
|
Nine months ended September 30,
|
||||||
|
2017
|
|
2016
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net earnings
|
$
|
527,900
|
|
|
$
|
476,564
|
|
Adjustments to reconcile net earnings to cash flows from operating activities:
|
|
|
|
||||
Depreciation and amortization of property, plant and equipment
|
36,776
|
|
|
27,954
|
|
||
Amortization of intangible assets
|
221,518
|
|
|
149,149
|
|
||
Amortization of deferred financing costs
|
5,463
|
|
|
4,080
|
|
||
Non-cash stock compensation
|
67,598
|
|
|
60,480
|
|
||
Gain on sale of assets
|
(9,393
|
)
|
|
—
|
|
||
Changes in operating assets and liabilities, net of acquired businesses:
|
|
|
|
||||
Accounts receivable
|
30,074
|
|
|
(1,660
|
)
|
||
Unbilled receivables
|
(27,186
|
)
|
|
3,684
|
|
||
Inventories
|
(19,577
|
)
|
|
(5,916
|
)
|
||
Accounts payable and accrued liabilities
|
48,276
|
|
|
17,273
|
|
||
Deferred revenue
|
50,554
|
|
|
19,692
|
|
||
Income taxes
|
(48,370
|
)
|
|
(52,728
|
)
|
||
Other, net
|
(17,900
|
)
|
|
(5,199
|
)
|
||
Cash provided by operating activities
|
865,733
|
|
|
693,373
|
|
||
|
|
|
|
||||
Cash flows from investing activities:
|
|
|
|
||||
Acquisitions of businesses, net of cash acquired
|
(88,070
|
)
|
|
(277,587
|
)
|
||
Capital expenditures
|
(35,898
|
)
|
|
(26,933
|
)
|
||
Capitalized software expenditures
|
(8,043
|
)
|
|
(1,528
|
)
|
||
Proceeds from sale of assets
|
10,614
|
|
|
866
|
|
||
Other, net
|
(6,932
|
)
|
|
1,564
|
|
||
Cash used in investing activities
|
(128,329
|
)
|
|
(303,618
|
)
|
||
|
|
|
|
||||
Cash flows from financing activities:
|
|
|
|
||||
Payments under revolving line of credit, net
|
(880,000
|
)
|
|
(180,000
|
)
|
||
Principal payments on convertible notes
|
—
|
|
|
(4,010
|
)
|
||
Cash premiums paid on convertible note conversions
|
—
|
|
|
(13,308
|
)
|
||
Cash dividends to stockholders
|
(106,480
|
)
|
|
(90,632
|
)
|
||
Proceeds from stock-based compensation, net
|
32,932
|
|
|
13,895
|
|
||
Treasury stock sales
|
3,194
|
|
|
2,576
|
|
||
Other
|
179
|
|
|
(7,816
|
)
|
||
Cash used in financing activities
|
(950,175
|
)
|
|
(279,295
|
)
|
||
|
|
|
|
||||
Effect of foreign currency exchange rate changes on cash
|
61,187
|
|
|
(6,701
|
)
|
||
|
|
|
|
||||
Net (decrease)/increase in cash and cash equivalents
|
(151,584
|
)
|
|
103,759
|
|
||
|
|
|
|
||||
Cash and cash equivalents, beginning of period
|
757,200
|
|
|
778,511
|
|
||
|
|
|
|
||||
Cash and cash equivalents, end of period
|
$
|
605,616
|
|
|
$
|
882,270
|
|
|
Common
stock
|
|
Additional
paid-in
capital
|
|
Retained
earnings
|
|
Accumulated
other
comprehensive
loss
|
|
Treasury
stock
|
|
Total
|
||||||||||||
Balances at December 31, 2016
|
$
|
1,036
|
|
|
$
|
1,489,067
|
|
|
$
|
4,642,402
|
|
|
$
|
(324,739
|
)
|
|
$
|
(18,901
|
)
|
|
$
|
5,788,865
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net earnings
|
—
|
|
|
—
|
|
|
527,900
|
|
|
—
|
|
|
—
|
|
|
527,900
|
|
||||||
Stock option exercises
|
4
|
|
|
40,397
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
40,401
|
|
||||||
Treasury stock sold
|
—
|
|
|
3,040
|
|
|
—
|
|
|
—
|
|
|
154
|
|
|
3,194
|
|
||||||
Currency translation adjustments
|
—
|
|
|
—
|
|
|
—
|
|
|
147,462
|
|
|
—
|
|
|
147,462
|
|
||||||
Stock based compensation
|
—
|
|
|
66,010
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
66,010
|
|
||||||
Restricted stock activity
|
3
|
|
|
(7,475
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(7,472
|
)
|
||||||
Dividends declared
|
—
|
|
|
—
|
|
|
(107,376
|
)
|
|
—
|
|
|
—
|
|
|
(107,376
|
)
|
||||||
Balances at September 30, 2017
|
$
|
1,043
|
|
|
$
|
1,591,039
|
|
|
$
|
5,062,926
|
|
|
$
|
(177,277
|
)
|
|
$
|
(18,747
|
)
|
|
$
|
6,458,984
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||
Basic shares outstanding
|
102,303
|
|
|
101,372
|
|
|
102,091
|
|
|
101,231
|
|
Effect of potential common stock:
|
|
|
|
|
|
|
|
||||
Common stock awards
|
1,377
|
|
|
1,112
|
|
|
1,306
|
|
|
1,131
|
|
Senior subordinated convertible notes
|
—
|
|
|
38
|
|
|
—
|
|
|
62
|
|
Diluted shares outstanding
|
103,680
|
|
|
102,522
|
|
|
103,397
|
|
|
102,424
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Stock-based compensation
|
$
|
23,734
|
|
|
$
|
21,388
|
|
|
$
|
67,598
|
|
|
$
|
60,480
|
|
Tax effect recognized in net income
|
8,307
|
|
|
7,486
|
|
|
23,659
|
|
|
21,168
|
|
|
Nine months ended September 30,
|
||
|
2017
|
|
2016
|
Risk-free interest rate (%)
|
2.03
|
|
1.38
|
Expected option life (years)
|
5.26
|
|
5.20
|
Expected volatility (%)
|
18.76
|
|
21.63
|
Expected dividend yield (%)
|
0.67
|
|
0.70
|
|
September 30,
2017 |
|
December 31,
2016 |
||||
Raw materials and supplies
|
$
|
131,817
|
|
|
$
|
113,632
|
|
Work in process
|
29,172
|
|
|
24,290
|
|
||
Finished products
|
87,561
|
|
|
81,263
|
|
||
Inventory reserves
|
(39,244
|
)
|
|
(37,233
|
)
|
||
|
$
|
209,306
|
|
|
$
|
181,952
|
|
|
RF Technology
|
|
Medical &
Scientific Imaging
|
|
Industrial
Technology
|
|
Energy Systems
& Controls
|
|
Total
|
||||||||||
Balances at December 31, 2016
|
$
|
4,687,670
|
|
|
$
|
3,185,071
|
|
|
$
|
363,978
|
|
|
$
|
410,423
|
|
|
$
|
8,647,142
|
|
Additions
|
38,349
|
|
|
—
|
|
|
—
|
|
|
19,169
|
|
|
57,518
|
|
|||||
Other
|
22,385
|
|
|
3,264
|
|
|
—
|
|
|
—
|
|
|
25,649
|
|
|||||
Currency translation adjustments
|
20,528
|
|
|
19,922
|
|
|
13,656
|
|
|
9,541
|
|
|
63,647
|
|
|||||
Balances at September 30, 2017
|
$
|
4,768,932
|
|
|
$
|
3,208,257
|
|
|
$
|
377,634
|
|
|
$
|
439,133
|
|
|
$
|
8,793,956
|
|
|
Cost
|
|
Accumulated
amortization
|
|
Net book
value
|
||||||
Assets subject to amortization:
|
|
|
|
|
|
||||||
Customer related intangibles
|
$
|
3,272,081
|
|
|
$
|
(712,718
|
)
|
|
$
|
2,559,363
|
|
Unpatented technology
|
462,152
|
|
|
(144,025
|
)
|
|
318,127
|
|
|||
Software
|
184,761
|
|
|
(56,882
|
)
|
|
127,879
|
|
|||
Patents and other protective rights
|
24,656
|
|
|
(20,399
|
)
|
|
4,257
|
|
|||
Trade names
|
6,591
|
|
|
(653
|
)
|
|
5,938
|
|
|||
Assets not subject to amortization:
|
|
|
|
|
|
||||||
Trade names
|
578,279
|
|
|
—
|
|
|
578,279
|
|
|||
In process research and development
|
62,000
|
|
|
—
|
|
|
62,000
|
|
|||
Balances at December 31, 2016
|
$
|
4,590,520
|
|
|
$
|
(934,677
|
)
|
|
$
|
3,655,843
|
|
Assets subject to amortization:
|
|
|
|
|
|
||||||
Customer related intangibles
|
$
|
3,313,342
|
|
|
$
|
(863,741
|
)
|
|
$
|
2,449,601
|
|
Unpatented technology
|
539,892
|
|
|
(193,223
|
)
|
|
346,669
|
|
|||
Software
|
185,305
|
|
|
(77,894
|
)
|
|
107,411
|
|
|||
Patents and other protective rights
|
26,034
|
|
|
(22,007
|
)
|
|
4,027
|
|
|||
Trade names
|
6,638
|
|
|
(1,466
|
)
|
|
5,172
|
|
|||
Assets not subject to amortization:
|
|
|
|
|
|
||||||
Trade names
|
588,349
|
|
|
—
|
|
|
588,349
|
|
|||
In process research and development
|
1,458
|
|
|
—
|
|
|
1,458
|
|
|||
Balances at September 30, 2017
|
$
|
4,661,018
|
|
|
$
|
(1,158,331
|
)
|
|
$
|
3,502,687
|
|
$400 million 1.850% senior notes due 2017
|
$
|
400
|
|
$800 million 2.050% senior notes due 2018
|
802
|
|
|
$500 million 6.250% senior notes due 2019
|
539
|
|
|
$600 million 3.000% senior notes due 2020
|
612
|
|
|
$500 million 2.800% senior notes due 2021
|
504
|
|
|
$500 million 3.125% senior notes due 2022
|
513
|
|
|
$300 million 3.850% senior notes due 2025
|
311
|
|
|
$700 million 3.800% senior notes due 2026
|
723
|
|
Balances at December 31, 2016
|
$
|
10,548
|
|
Additions charged to costs and expenses
|
9,418
|
|
|
Deductions
|
(8,941
|
)
|
|
Other
|
149
|
|
|
Balances at September 30, 2017
|
$
|
11,174
|
|
|
Three months ended September 30,
|
|
|
|
Nine months ended September 30,
|
|
|
||||||||||||||
|
2017
|
|
2016
|
|
Change
|
|
2017
|
|
2016
|
|
Change
|
||||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
RF Technology
|
$
|
480,572
|
|
|
$
|
303,565
|
|
|
58.3
|
%
|
|
$
|
1,370,688
|
|
|
$
|
872,536
|
|
|
57.1
|
%
|
Medical & Scientific Imaging
|
343,639
|
|
|
338,027
|
|
|
1.7
|
%
|
|
1,042,638
|
|
|
1,010,826
|
|
|
3.1
|
%
|
||||
Industrial Technology
|
200,442
|
|
|
178,317
|
|
|
12.4
|
%
|
|
576,713
|
|
|
528,179
|
|
|
9.2
|
%
|
||||
Energy Systems & Controls
|
135,259
|
|
|
125,235
|
|
|
8.0
|
%
|
|
390,849
|
|
|
367,584
|
|
|
6.3
|
%
|
||||
Total
|
$
|
1,159,912
|
|
|
$
|
945,144
|
|
|
22.7
|
%
|
|
$
|
3,380,888
|
|
|
$
|
2,779,125
|
|
|
21.7
|
%
|
Gross profit:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
RF Technology
|
$
|
298,883
|
|
|
$
|
169,123
|
|
|
76.7
|
%
|
|
$
|
830,096
|
|
|
$
|
492,493
|
|
|
68.5
|
%
|
Medical & Scientific Imaging
|
247,138
|
|
|
247,432
|
|
|
(0.1
|
)%
|
|
753,096
|
|
|
740,725
|
|
|
1.7
|
%
|
||||
Industrial Technology
|
102,092
|
|
|
90,950
|
|
|
12.3
|
%
|
|
293,410
|
|
|
266,679
|
|
|
10.0
|
%
|
||||
Energy Systems & Controls
|
78,307
|
|
|
70,988
|
|
|
10.3
|
%
|
|
223,082
|
|
|
205,635
|
|
|
8.5
|
%
|
||||
Total
|
$
|
726,420
|
|
|
$
|
578,493
|
|
|
25.6
|
%
|
|
$
|
2,099,684
|
|
|
$
|
1,705,532
|
|
|
23.1
|
%
|
Operating profit*:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
RF Technology
|
$
|
134,148
|
|
|
$
|
94,785
|
|
|
41.5
|
%
|
|
$
|
342,690
|
|
|
$
|
272,905
|
|
|
25.6
|
%
|
Medical & Scientific Imaging
|
115,506
|
|
|
118,979
|
|
|
(2.9
|
)%
|
|
356,614
|
|
|
347,706
|
|
|
2.6
|
%
|
||||
Industrial Technology
|
62,255
|
|
|
52,800
|
|
|
17.9
|
%
|
|
174,117
|
|
|
150,850
|
|
|
15.4
|
%
|
||||
Energy Systems & Controls
|
36,351
|
|
|
31,777
|
|
|
14.4
|
%
|
|
99,454
|
|
|
83,728
|
|
|
18.8
|
%
|
||||
Total
|
$
|
348,260
|
|
|
$
|
298,341
|
|
|
16.7
|
%
|
|
$
|
972,875
|
|
|
$
|
855,189
|
|
|
13.8
|
%
|
Long-lived assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
RF Technology
|
$
|
81,863
|
|
|
$
|
30,984
|
|
|
164.2
|
%
|
|
|
|
|
|
|
|||||
Medical & Scientific Imaging
|
43,858
|
|
|
38,793
|
|
|
13.1
|
%
|
|
|
|
|
|
|
|||||||
Industrial Technology
|
32,198
|
|
|
35,584
|
|
|
(9.5
|
)%
|
|
|
|
|
|
|
|||||||
Energy Systems & Controls
|
9,461
|
|
|
10,720
|
|
|
(11.7
|
)%
|
|
|
|
|
|
|
|||||||
Total
|
$
|
167,380
|
|
|
$
|
116,081
|
|
|
44.2
|
%
|
|
|
|
|
|
|
ITEM 2.
|
MANAGMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
•
|
general economic conditions;
|
•
|
difficulty making acquisitions and successfully integrating acquired businesses;
|
•
|
any unforeseen liabilities associated with future acquisitions;
|
•
|
limitations on our business imposed by our indebtedness;
|
•
|
unfavorable changes in foreign exchange rates;
|
•
|
difficulties associated with exports;
|
•
|
risks and costs associated with our international sales and operations;
|
•
|
rising interest rates;
|
•
|
product liability and insurance risks;
|
•
|
increased warranty exposure;
|
•
|
future competition;
|
•
|
the cyclical nature of some of our markets;
|
•
|
reduction of business with large customers;
|
•
|
risks associated with government contracts;
|
•
|
changes in the supply of, or price for, labor, raw materials, parts and components;
|
•
|
environmental compliance costs and liabilities;
|
•
|
risks and costs associated with asbestos-related litigation;
|
•
|
potential write-offs of our substantial goodwill and other intangible assets;
|
•
|
our ability to successfully develop new products;
|
•
|
failure to protect our intellectual property;
|
•
|
the effect of, or change in, government regulations (including tax);
|
•
|
economic disruption caused by terrorist attacks, including cybersecurity threats, health crises or other unforeseen events; and
|
•
|
the factors discussed in other reports filed with the SEC.
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net revenues:
|
|
|
|
|
|
|
|
||||||||
RF Technology
|
$
|
480,572
|
|
|
$
|
303,565
|
|
|
$
|
1,370,688
|
|
|
$
|
872,536
|
|
Medical & Scientific Imaging
|
343,639
|
|
|
338,027
|
|
|
1,042,638
|
|
|
1,010,826
|
|
||||
Industrial Technology
|
200,442
|
|
|
178,317
|
|
|
576,713
|
|
|
528,179
|
|
||||
Energy Systems & Controls
|
135,259
|
|
|
125,235
|
|
|
390,849
|
|
|
367,584
|
|
||||
Total
|
$
|
1,159,912
|
|
|
$
|
945,144
|
|
|
$
|
3,380,888
|
|
|
$
|
2,779,125
|
|
Gross margin:
|
|
|
|
|
|
|
|
||||||||
RF Technology
|
62.2
|
%
|
|
55.7
|
%
|
|
60.6
|
%
|
|
56.4
|
%
|
||||
Medical & Scientific Imaging
|
71.9
|
|
|
73.2
|
|
|
72.2
|
|
|
73.3
|
|
||||
Industrial Technology
|
50.9
|
|
|
51.0
|
|
|
50.9
|
|
|
50.5
|
|
||||
Energy Systems & Controls
|
57.9
|
|
|
56.7
|
|
|
57.1
|
|
|
55.9
|
|
||||
Total
|
62.6
|
|
|
61.2
|
|
|
62.1
|
|
|
61.4
|
|
||||
Selling, general & administrative expenses:
|
|
|
|
|
|
|
|
||||||||
RF Technology
|
34.3
|
%
|
|
24.5
|
%
|
|
35.6
|
%
|
|
25.2
|
%
|
||||
Medical & Scientific Imaging
|
38.3
|
|
|
38.0
|
|
|
38.0
|
|
|
38.9
|
|
||||
Industrial Technology
|
19.9
|
|
|
21.4
|
|
|
20.7
|
|
|
21.9
|
|
||||
Energy Systems & Controls
|
31.0
|
|
|
31.3
|
|
|
31.6
|
|
|
33.2
|
|
||||
Total
|
32.6
|
|
|
29.6
|
|
|
33.3
|
|
|
30.6
|
|
||||
Segment operating margin:
|
|
|
|
|
|
|
|
||||||||
RF Technology
|
27.9
|
%
|
|
31.2
|
%
|
|
25.0
|
%
|
|
31.3
|
%
|
||||
Medical & Scientific Imaging
|
33.6
|
|
|
35.2
|
|
|
34.2
|
|
|
34.4
|
|
||||
Industrial Technology
|
31.1
|
|
|
29.6
|
|
|
30.2
|
|
|
28.6
|
|
||||
Energy Systems & Controls
|
26.9
|
|
|
25.4
|
|
|
25.4
|
|
|
22.8
|
|
||||
Total
|
30.0
|
|
|
31.6
|
|
|
28.8
|
|
|
30.8
|
|
||||
Corporate administrative expenses
|
(3.2
|
)
|
|
(3.3
|
)
|
|
(3.2
|
)
|
|
(3.2
|
)
|
||||
|
26.8
|
|
|
28.3
|
|
|
25.5
|
|
|
27.5
|
|
||||
Interest expense, net
|
(3.9
|
)
|
|
(2.8
|
)
|
|
(4.1
|
)
|
|
(2.9
|
)
|
||||
Other income/(expense), net
|
(0.1
|
)
|
|
(0.1
|
)
|
|
0.2
|
|
|
(0.1
|
)
|
||||
Earnings before income taxes
|
22.8
|
|
|
25.4
|
|
|
21.6
|
|
|
24.6
|
|
||||
Income taxes
|
(6.4
|
)
|
|
(7.7
|
)
|
|
(6.0
|
)
|
|
(7.4
|
)
|
||||
Net earnings
|
16.4
|
%
|
|
17.7
|
%
|
|
15.6
|
%
|
|
17.1
|
%
|
|
Order backlog as of
|
||||||
|
September 30,
|
||||||
|
2017
|
|
2016
|
||||
|
(in thousands)
|
||||||
RF Technology
|
$
|
956,264
|
|
|
$
|
563,716
|
|
Medical & Scientific Imaging
|
441,508
|
|
|
396,620
|
|
||
Industrial Technology
|
98,541
|
|
|
69,020
|
|
||
Energy Systems & Controls
|
96,481
|
|
|
90,699
|
|
||
Total
|
$
|
1,592,794
|
|
|
$
|
1,120,055
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||||
Cash provided by/(used in):
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Operating activities
|
$
|
315.6
|
|
|
$
|
316.5
|
|
|
$
|
865.7
|
|
|
$
|
693.4
|
|
Investing activities
|
(66.3
|
)
|
|
(10.4
|
)
|
|
(128.3
|
)
|
|
(303.6
|
)
|
||||
Financing activities
|
(331.8
|
)
|
|
(47.3
|
)
|
|
(950.2
|
)
|
|
(279.3
|
)
|
$400 million 1.850% senior notes due 2017
|
$
|
400,000
|
|
$800 million 2.050% senior notes due 2018
|
800,000
|
|
|
$500 million 6.250% senior notes due 2019
|
500,000
|
|
|
$600 million 3.000% senior notes due 2020
|
600,000
|
|
|
$500 million 2.800% senior notes due 2021
|
500,000
|
|
|
$500 million 3.125% senior notes due 2022
|
500,000
|
|
|
$300 million 3.850% senior notes due 2025
|
300,000
|
|
|
$700 million 3.800% senior notes due 2026
|
700,000
|
|
|
Unsecured credit facility
|
1,050,000
|
|
|
Deferred finance costs
|
(19,023
|
)
|
|
Other
|
3,278
|
|
|
Total debt, net of deferred finance costs
|
5,334,255
|
|
|
Less current portion
|
401,534
|
|
|
Long-term debt, net of deferred finance costs
|
$
|
4,932,721
|
|
|
September 30,
2017 |
|
December 31,
2016 |
||||
Total debt
|
$
|
5,334,255
|
|
|
$
|
6,209,536
|
|
Cash
|
(605,616
|
)
|
|
(757,200
|
)
|
||
Net debt
|
4,728,639
|
|
|
5,452,336
|
|
||
Stockholders' equity
|
6,458,984
|
|
|
5,788,865
|
|
||
Total net capital
|
$
|
11,187,623
|
|
|
$
|
11,241,201
|
|
|
|
|
|
||||
Net debt / total net capital
|
42.3
|
%
|
|
48.5
|
%
|
31.1
|
|
|
Rule 13a-14(a)/15d-14(a), Certification of the Chief Executive Officer, filed herewith.
|
|
|
|
|
31.2
|
|
|
Rule 13a-14(a)/15d-14(a), Certification of the Chief Financial Officer, filed herewith.
|
|
|
|
|
32.1
|
|
|
Section 1350 Certification of the Chief Executive and Chief Financial Officers, furnished herewith.
|
|
|
|
|
101.INS
|
|
|
XBRL Instance Document, filed herewith.
|
|
|
|
|
101.SCH
|
|
|
XBRL Taxonomy Extension Schema Document, filed herewith.
|
|
|
|
|
101.CAL
|
|
|
XBRL Taxonomy Extension Calculation Linkbase Document, filed herewith.
|
|
|
|
|
101.DEF
|
|
|
XBRL Taxonomy Extension Definition Linkbase Document, filed herewith.
|
|
|
|
|
101.LAB
|
|
|
XBRL Taxonomy Extension Label Linkbase Document, filed herewith.
|
|
|
|
|
101.PRE
|
|
|
XBRL Taxonomy Extension Presentation Linkbase Document, filed herewith.
|
Number
|
|
Exhibit
|
|
|
|
|
|
31.1
|
|
|
|
|
|
|
|
31.2
|
|
|
|
|
|
|
|
32.1
|
|
|
|
|
|
|
|
101.INS
|
|
|
XBRL Instance Document, filed herewith.
|
|
|
|
|
101.SCH
|
|
|
XBRL Taxonomy Extension Schema Document, filed herewith.
|
|
|
|
|
101.CAL
|
|
|
XBRL Taxonomy Extension Calculation Linkbase Document, filed herewith.
|
|
|
|
|
101.DEF
|
|
|
XBRL Taxonomy Extension Definition Linkbase Document, filed herewith.
|
|
|
|
|
101.LAB
|
|
|
XBRL Taxonomy Extension Label Linkbase Document, filed herewith.
|
|
|
|
|
101.PRE
|
|
|
XBRL Taxonomy Extension Presentation Linkbase Document, filed herewith.
|
/s/ Brian D. Jellison
|
|
Chairman of the Board, President,
|
November 6, 2017
|
Brian D. Jellison
|
|
and Chief Executive Officer
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
/s/ Robert Crisci
|
|
Vice President and Chief Financial Officer
|
November 6, 2017
|
Robert Crisci
|
|
(Principal Financial Officer)
|
|
/s/ Jason Conley
|
|
Vice President and Controller
|
November 6, 2017
|
Jason Conley
|
|
(Principal Accounting Officer)
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|